rhBNP, Selenium Recycling, and Renal Ferroptosis
2026-08-20
This study identifies selenocysteine lyase 1 (SCLY)-dependent selenium recycling as a mechanistic basis for the renal protection conferred by recombinant human brain natriuretic peptide (rhBNP) during ischemia-reperfusion injury. By integrating clinical observations, rat models, transcriptomics, and HK2-cell perturbation experiments, the work connects rhBNP signaling with suppression of ferroptosis and provides a testable target for acute kidney injury research.
Angiotensin Peptides and SARS-CoV-2 Spike Binding
2026-08-20
A 2025 study found that naturally occurring angiotensin fragments can increase SARS-CoV-2 spike-protein binding to host receptors, with particularly strong effects observed for shorter peptides and angiotensin IV. The work connects renin–angiotensin system biology with viral receptor recognition and provides a comparative framework for testing peptide structure, receptor selectivity, and translational relevance.
Nullscript: HDAC Inhibition as an Assay Strategy
2026-08-19
Nullscript is a histone deacetylase inhibitor with an unusual separation between HDAC inhibition and transcriptional facilitation. This article explains how that profile can sharpen cardiac ischemia/reperfusion assays and help researchers interpret epigenetic contributions to injury biology without confusing correlation with mechanism.
Toremifene vs Tamoxifen in Advanced Breast Cancer
2026-08-19
This Cochrane review directly compared toremifene and tamoxifen for advanced breast cancer, focusing on tumor response, progression, survival, and treatment-related adverse events. Its main practical implication is that available randomized evidence did not demonstrate a consistent efficacy or safety advantage for either endocrine agent, while limitations in trial reporting constrain claims of equivalence.
Dynasore Workflows for Endocytosis Research
2026-08-18
Dynasore is a reversible dynamin GTPase inhibitor for separating membrane-fission events from downstream trafficking and signaling. This practical guide translates pharmacology, cargo-uptake assays, and the GCRV entry study into optimized workflows for endocytosis research, neuronal models, and carefully controlled pathway experiments.
FITC Goat Anti-Mouse IgG (H+L) Antibody Guide
2026-08-18
This reagent provides fluorescein-based detection of mouse IgG primary antibodies in immunofluorescence, fluorescence microscopy, and flow cytometry workflows. It should not be assumed suitable for non-mouse primary antibodies, live-cell assays, or unvalidated assay formats without compatibility testing.
Latrunculin B for Transient Actin Studies
2026-08-17
Latrunculin B provides reversible, short-duration control of actin filament assembly for live-cell imaging, cytoskeletal organization studies, and entry-pathway experiments. Its value is greatest when exposure time, serum effects, and orthogonal controls are designed into the workflow rather than treated as afterthoughts.
Bradykinin (BA5201): Practical Research Workflow
2026-08-17
Bradykinin (BA5201) provides a defined research peptide for acute studies of endothelium-dependent vasodilation, vascular permeability, smooth muscle contraction, pain mechanisms, and inflammation signaling. It is intended for controlled scientific experiments only; it should not be used for diagnosis, treatment, or direct clinical blood pressure management.
FGF4-FGFR1 Signaling Protects Podocytes in DKD
2026-08-16
This Nature Communications study identifies podocyte-secreted FGF4 as an endogenous regulator of glomerular integrity in diabetic kidney disease. Genetic loss-of-function, recombinant FGF4 treatment, and human podocyte experiments converge on an FGFR1–AMPK–FOXO1 pathway that limits oxidative stress and apoptosis, providing a mechanistic basis for protecting podocyte survival.
Latrunculin B: Actin Control for Translational Insight
2026-08-15
Latrunculin B is more than a cytoskeletal perturbagen: its reversible control of G-actin provides a rigorous way to test pathway dependence, define assay windows, and interpret negative results in translational cell biology and antiviral research.
CX-4945: CK2 Target Engagement Beyond Cancer
2026-08-14
CX-4945 (Silmitasertib) is a selective ATP-competitive CK2 inhibitor for connecting kinase target engagement with cancer and host-pathogen biology. This article develops a causal assay framework based on CK2α-dependent viral replication, rather than repeating a conventional inhibitor protocol.
Ciprofloxacin Hydrochloride Assay Workflows
2026-08-14
Build more informative antibacterial assays with Ciprofloxacin hydrochloride, from MIC and combination matrices to single-cell survival and SOS-response measurements. This workflow-focused guide also separates DNA-damage biology from host immunomodulatory readouts, helping researchers avoid misleading endpoint comparisons.
DNA Removal as a Translational Quality Variable
2026-08-13
A mechanistic and strategic guide to using DNase I (RNase-free) for RNA integrity, assay confidence, and translational reproducibility.
Atrial Natriuretic Peptide: Evidence-Led Use
2026-08-13
A practical, evidence-led guide to Atrial Natriuretic Peptide and ANP peptide hormone research. It connects product identity, cardiovascular assay design, storage decisions, and lessons from an adiponectin neuroinflammation study without overstating cross-domain evidence.
CBD, FAAH, and Orofacial Inflammatory Pain
2026-08-12
A 2026 Brain Research Bulletin study shows that cannabidiol (CBD) can reduce both inflammatory orofacial nociception and pain-associated affective and cognitive deficits in mice. Its main contribution is a multilevel mechanism linking peripheral FAAH and inflammatory signaling with central endocannabinoid, trigeminal, and amygdala serotonin activity.
566 records 8/38 page Previous Next First page 上5页 678910 下5页 Last page